Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 96,699
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12594278 | Method for treatment of muscular dystrophy | 🖼🧊📄§ | 2026-04-07 | 2040-07-16 | 0 | 31 |
| 12595295 | Dosing regimes for treatment of synucleinopathies | 🖼🧊📄§ | 2026-04-07 | 2040-07-23 | 0 | 31 |
| 12595280 | Phosphoramidates for the treatment of hepatitis B virus | 🖼🧊📄§ | 2026-04-07 | 2044-04-11 | 0 | 31 |
| 12595285 | LMP-1 expressing cells and methods of use thereof | 🖼🧊📄§ | 2026-04-07 | 2042-05-13 | 0 | 31 |
| 12595250 | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses | 🖼🧊📄§ | 2026-04-07 | 2042-06-15 | 0 | 31 |
| 12595243 | Modulators of extracellular signal-regulated kinase | 🖼🧊📄§ | 2026-04-07 | 2044-10-18 | 0 | 31 |
| 12594272 | 2-bromo-lysergic acid diethylamide for substance abuse | 🖼🧊📄§ | 2026-04-07 | 2041-03-25 | 0 | 31 |
| 12595300 | Anti-human P40 protein domain antibody and use thereof | 🖼🧊📄§ | 2026-04-07 | 2040-07-28 | 0 | 31 |
| 12595293 | Anti-follicle stimulating hormone receptor antibodies | 🖼🧊📄§ | 2026-04-07 | 2039-08-09 | 0 | 31 |
| 12595232 | DRG-MDM2-1 for use as a novel Mouse Double Minute 2 (MDM2) inhibitor | 🖼🧊📄§ | 2026-04-07 | 2041-02-16 | 0 | 31 |
| 12595302 | CLDN18.2 binding molecule | 🖼🧊📄§ | 2026-04-07 | 2040-05-21 | 0 | 31 |
| 12595517 | Method to treat and stratify a patient suffering from a cancer | 🖼🧊📄§ | 2026-04-07 | 2041-09-13 | 0 | 31 |
| 12594308 | Methods of preparing a postbiotic composition | 🖼🧊📄§ | 2026-04-07 | 2044-10-08 | 0 | 31 |
| 12594320 | Method for treating checkpoint inhibitors induced adverse events | 🖼🧊📄§ | 2026-04-07 | 2040-02-03 | 0 | 31 |
| 12594234 | Use of an epilobium fleischeri extract | 🖼🧊📄§ | 2026-04-07 | 2041-09-17 | 0 | 31 |
| 12595307 | Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors | 🖼🧊📄§ | 2026-04-07 | 2041-06-09 | 0 | 31 |
| 12594254 | Intranasal administration of n-acetylcysteine and uses thereof | 🖼🧊📄§ | 2026-04-07 | 2043-02-07 | 0 | 31 |
| 12594245 | Dry powder formulations for messenger RNA | 🖼🧊📄§ | 2026-04-07 | 2042-05-16 | 0 | 31 |
| 12594224 | Oral care compositions and methods of use | 🖼🧊📄§ | 2026-04-07 | 2042-09-23 | 0 | 31 |
| 12594275 | Immunophilin binding agents and uses thereof | 🖼🧊📄§ | 2026-04-07 | 2040-02-06 | 0 | 31 |
| 12595469 | Treatment of retinitis pigmentosa using improved engineered meganucleases | 🖼🧊📄§ | 2026-04-07 | 2041-05-11 | 0 | 31 |
| 12596122 | LILRB2 antibodies and uses thereof | 🖼🧊📄§ | 2026-04-07 | 2041-01-28 | 0 | 31 |
| 12595464 | Method of producing retinal pigment epithelial cell | 🖼🧊📄§ | 2026-04-07 | 2045-02-25 | 0 | 31 |
| 12595485 | Modulation of prekallikrein (PKK) expression | 🖼🧊📄§ | 2026-04-07 | 2043-10-18 | 0 | 31 |
| 12594225 | Hair cleansing composition | 🖼🧊📄§ | 2026-04-07 | 2041-09-29 | 0 | 31 |
| 12594227 | Tetrapeptide and compositions comprising tetrapeptides | 🖼🧊📄§ | 2026-04-07 | 2041-11-16 | 0 | 31 |
| 12594229 | Personal care compositions and methods for the same | 🖼🧊📄§ | 2026-04-07 | 2040-12-04 | 0 | 31 |
| 12594230 | Sphingolipid containing salicylic acid derivative and composition comprising same | 🖼🧊📄§ | 2026-04-07 | 2040-12-28 | 0 | 31 |
| 12594232 | Personal care compositions and methods for using such compositions | 🖼🧊📄§ | 2026-04-07 | 2037-04-05 | 0 | 31 |
| 12594235 | Intraoral cleaning tablet | 🖼🧊📄§ | 2026-04-07 | 2045-09-24 | 0 | 31 |
| 12594233 | Fat and/or wax activated by means of the water-insoluble fraction of Carica papaya sap | 🖼🧊📄§ | 2026-04-07 | 2042-09-07 | 0 | 31 |
| 12594231 | Emulsified composition and cosmetic material | 🖼🧊📄§ | 2026-04-07 | 2041-12-07 | 0 | 31 |
| 12594237 | Mucoadhesive gel composition | 🖼🧊📄§ | 2026-04-07 | 2043-02-06 | 0 | 31 |
| 12594241 | Topiramate oral liquid suspension and use thereof | 🖼🧊📄§ | 2026-04-07 | 2043-09-07 | 0 | 31 |
| 12594242 | Lipid compounds and lipid nanoparticle compositions | 🖼🧊📄§ | 2026-04-07 | 2044-03-26 | 0 | 31 |
| 12594243 | Pharmaceutical formulations | 🖼🧊📄§ | 2026-04-07 | 2043-11-03 | 0 | 31 |
| 12594240 | Artificial vitreous humor for the investigation of drugs and drug formulations | 🖼🧊📄§ | 2026-04-07 | 2043-04-11 | 0 | 31 |
| 12594239 | Protection of biological species from degradation | 🖼🧊📄§ | 2026-04-07 | 2042-07-22 | 0 | 31 |
| 12594238 | Low hygroscopicity active powder compositions | 🖼🧊📄§ | 2026-04-07 | 2041-08-31 | 0 | 31 |
| 12594248 | Stress management in human subjects in need thereof | 🖼🧊📄§ | 2026-04-07 | 2041-01-13 | 0 | 31 |
| 12594251 | Benzalkonium chloride foruse in treating conjunctivitis and/or covid-19 | 🖼🧊📄§ | 2026-04-07 | 2041-10-14 | 0 | 31 |
| 12594247 | Edged cataplasm and manufacturing process | 🖼🧊📄§ | 2026-04-07 | 2043-02-07 | 0 | 31 |
| 12594250 | Prevention of accumulated tolerance to stimulant medication for the treatment of ADHD | 🖼🧊📄§ | 2026-04-07 | 2045-04-10 | 0 | 31 |
| 12594253 | HIV inhibitors | 🖼🧊📄§ | 2026-04-07 | 2039-07-24 | 0 | 31 |
| 12594252 | Methods for treating inflammatory skin conditions | 🖼🧊📄§ | 2026-04-07 | 2042-06-20 | 0 | 31 |
| 12594258 | Inhibitors of MHC-I Nef downmodulation for treating HIV | 🖼🧊📄§ | 2026-04-07 | 2040-12-16 | 0 | 31 |
| 12594263 | CBL inhibitors and compositions for expansion of immune cells | 🖼🧊📄§ | 2026-04-07 | 2040-09-23 | 0 | 31 |
| 12594260 | Topical formulations for infections | 🖼🧊📄§ | 2026-04-07 | 2044-06-28 | 0 | 31 |
| 12594262 | CAI nanoemulsions | 🖼🧊📄§ | 2026-04-07 | 2040-12-18 | 0 | 31 |
| 12594264 | Modulators of alpha-synuclein proteolysis and associated methods of use | 🖼🧊📄§ | 2026-04-07 | 2043-09-18 | 0 | 31 |